Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders-Reference-Cited by-同舟云学术

Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders

Published:2018-02-27 Issue:5 Volume:67 Page:825-834
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Kähler Katharina C., ,Eigentler Thomas K.,Gesierich Anja,Heinzerling Lucie,Loquai Carmen,Meier Friedegund,Meiss Frank,Pföhler Claudia,Schlaak Max,Terheyden Patrick,Thoms Kai M.,Ziemer Mirjana,Zimmer Lisa,Gutzmer Ralf

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/article/10.1007/s00262-018-2134-z/fulltext.html

Reference21 articles.

1. Ma Q, Shilkrut M, Li M, Barber BL, Zhao Z (2018) Prevalence of autoimmune comorbidities in patients with metastatic melanoma in the US. Value Health 19(3):A135

2. Johnson DB, Sullivan RJ, Ott PA, Carlino MS4, Khushalani NI, Ye F, Guminski A, Puzanov I, Lawrence DP, Buchbinder E, Mudigonda T, Spencer K, Bender C, Lee J, Kaufman HL, Menzies AM, Hassel JC, Mehnert JM, Sosman JA, Long GV, Clark JI (2016) Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2:234–240

3. Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong AN, Park JJ, McQuade JL, Shoushtari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, Davies MA, Sandhu SK, Long GV (2017) Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 28:368–376

4. Gutzmer R, Koop A, Meier F, Hassel JC, Terheyden P, Zimmer L, Heinzerling L, Ugurel S, Pföhler C, Gesierich A, Livingstone E, Satzger I, Kähler KC (2017) Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur J Cancer 75:24–32

5. Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, Bergmann T, Bockmeyer CL, Eigentler T, Fluck M, Garbe C, Gutzmer R, Grabbe S, Hauschild A, Hein R, Hundorfean G, Justich A, Keller U, Klein C, Mateus C, Mohr P, Paetzold S, Satzger I, Schadendorf D, Schlaeppi M, Schuler G, Schuler-Thurner B, Trefzer U, Ulrich J, Vaubel J, von Moos R, Weder P, Wilhelm T, Göppner D, Dummer R, Heinzerling LM (2013) The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One 8:e53745

Cited by 96 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease;European Journal of Cancer;2024-08

2. Anti-PD-L1 antibody retains antitumour effects while mitigating immunotherapy-related colitis in bladder cancer-bearing mice after CT-mediated intratumoral delivery;International Immunopharmacology;2024-08

4. Immune Checkpoint Inhibitor-Induced Psoriasis;Dermatologic Clinics;2024-07

5. Immune checkpoint inhibitors in Cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysis;BMC Cancer;2024-04-17